Market Spotlight: Multiple Myeloma Disease Coverage 

 Disease Overview

Multiple myeloma is characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. Almost all cases occur in individuals aged over 40 years, and age at diagnosis has an impact on patient outcome, especially in terms of the treatment options available. Most patients will receive at least three lines of treatment, and eligible patients will receive stem cell transplantation.

Market Snapshot

Multiple myeloma drugs market growth will be driven by label expansions and new launches, but will be moderated by genericization of Revlimid and Velcade.

Velcade and Revlimid dominate early treatment settings, but are replaced by newer drugs as patients relapse and become refractory to treatment.

The incident population is forecast to undergo a substantial 41% increase from 56,770 cases in 2016 to 80,290 in 2036.

The approvals of Empliciti and Darzalex could dramatically change the treatment of MM, as they represent much-needed new treatment options for relapsed MM patients.

Keytruda has an extensive development program and promising early-phase data in multiple myeloma.

Multiple myeloma drugs will enjoy reimbursement by US payers for the foreseeable future, while novel combinations will spur risk sharing in Europe.

Exclusive Sample Report @ https://www.reportsworldwide.com/enquiry?report_id=42604

Major TOC of Multiple Myeloma, Market:

1FORECAST: MULTIPLE MYELOMA
2Executive Summary
3Market Overview and Trends
4Market Definition and Methodology
5Darzalex (daratumumab)
6Empliciti (elotuzumab)
6Farydak (panobinostat)
7Keytruda (pembrolizumab)
8Kyprolis (carfilzomib)
9Ninlaro (ixazomib)
10 Pomalyst (pomalidomide)
11 Revlimid (lenalidomide)
12 selinexor
13 Thalomid (thalidomide)
14 Velcade (bortezomib)
15 Primary Research Methodology

16 TREATMENT: MULTIPLE MYELOMA
17 Executive Summary
18 Primary Research Methodology
19 Disease Definition and Diagnosis
20 Patient Segmentation
21 Country Treatment Trees
22 Current Treatment Options
23 Prescribing Trends

24 EPIDEMIOLOGY: MULTIPLE MYELOMA
25 Executive Summary
26 Disease Background
27 Sources and Methodology
28 Forecast
29 Epidemiologist Insight
30 Strengths and Limitations
31 Bibliography
32 Appendix: Additional Sources

 ………………………Continued

LIST OF FIGURES

1 Figure 1: Multiple myeloma market value across the US, Japan, and five major EU markets, by country, 2015–24
2 Figure 2: Multiple myeloma market value in the US, 2015−24
3 Figure 3: Multiple myeloma market value in the five major EU markets, 2015−24
4 Figure 4: Multiple myeloma market value in Japan, 2015−24
5 Figure 5: Combined sales of Darzalex, Empliciti, and Ninlaro in the US, Japan, and five major EU markets, by country, 2015−24
6 Figure 6: Sales of the major multiple myeloma drugs in the US, Japan, and five major EU markets, 2015−24
7 Figure 7: Sales of Kyprolis and Ninlaro in the US, Japan, and five major EU markets, 2015−24
8 Figure 8: Sales of Pomalyst and Revlimid in the US, Japan, and five major EU markets, 2015−24
9 Figure 9: Sales of Empliciti and Darzalex in the US, Japan, and five major EU markets, 2015−24
10 Figure 10: Patient-based forecast methodology for multiple myeloma
11 Figure 11: Price sources and calculations, by country

………………………Continued

Ask to Expertise @ https://www.reportsworldwide.com/enquiry?report_id=42604

About US:

Reportsworldwide.com is a one stop shop for all market intelligence needs. Our database of market research reports provides in depth coverage of 12 top industry verticals worldwide. We help you meet your market intelligence needs by mapping it with our database of market research reports including.

Contact Us:

Email: sales@reportsworldwide.com

Phone: +1 (617) 398-1947